BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23357083)

  • 21. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
    Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
    Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
    Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
    Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
    Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
    Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(2):549-58. PubMed ID: 17330952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
    Altai M; Varasteh Z; Andersson K; Eek A; Boerman O; Orlova A
    Cancer Biother Radiopharm; 2013 Apr; 28(3):187-95. PubMed ID: 23461385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.
    Ren G; Zhang R; Liu Z; Webster JM; Miao Z; Gambhir SS; Syud FA; Cheng Z
    J Nucl Med; 2009 Sep; 50(9):1492-9. PubMed ID: 19690041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.
    Garousi J; Lindbo S; Honarvar H; Velletta J; Mitran B; Altai M; Orlova A; Tolmachev V; Hober S
    Bioconjug Chem; 2016 Nov; 27(11):2678-2688. PubMed ID: 27740752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.
    Tolmachev V; Varasteh Z; Honarvar H; Hosseinimehr SJ; Eriksson O; Jonasson P; Frejd FY; Abrahmsen L; Orlova A
    J Nucl Med; 2014 Feb; 55(2):294-300. PubMed ID: 24408895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
    Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
    Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.
    Wållberg H; Orlova A
    Cancer Biother Radiopharm; 2008 Aug; 23(4):435-42. PubMed ID: 18771347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
    Westerlund K; Honarvar H; Tolmachev V; Eriksson Karlström A
    Bioconjug Chem; 2015 Aug; 26(8):1724-36. PubMed ID: 26086597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
    Hoppmann S; Miao Z; Liu S; Liu H; Ren G; Bao A; Cheng Z
    Bioconjug Chem; 2011 Mar; 22(3):413-21. PubMed ID: 21299201
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.